RISK ASSESSMENTS 34 3-MMC - Report on the risk assessment of

The Risk Assessment Report, which was submitted to the European Commission on 25 November 2021, examines the health and social risks of the drug, information on international trafficking and the involvement of organised crime, as well as a consideration of the potential implications of subjecting the drug to control measures. [...] On the basis of the Risk Assessment Report, the Commission adopted delegated act in order to add 3-MMC in to the definition of a drug in the Annex of the Council Framework Decision 2004/757/JHA (as amended by Directive (EU) 2017/2103). [...] The report has been prepared and drafted in accordance with the requirements of Article 5c of the Regulation as well as the conceptual framework and the procedure set out in the EMCDDA risk assessment operating guidelines. [...] In accordance with Article 5c of the Regulation, the meeting to assess the risks of 3-MMC was convened under the auspices of the Scientific Committee of the EMCDDA with the participation of six additional experts designated by the Director of the EMCDDA, acting on the advice of the Chairperson of the Scientific Committee, chosen from a list of experts approved by the Management Board of the EMCDDA. [...] Similar to other drugs, the purity of 3-MMC, as well as the presence of adulterants and diluents, depends on factors such as the location in the supply chain where the substance is obtained, as well the point in time and the geographical area.